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Abstract
The volume of the hippocampus measured with structural magnetic resonance imaging (MRI) is increasingly used as a
biomarker for Alzheimer’s disease (AD). However, the neuropathologic basis of structural MRI changes in the hippocampus
in the elderly has not been directly assessed. Postmortem MRI of the aging human brain, combined with histopathology,
could be an important tool to address this issue. Therefore, this study combined postmortem MRI and histopathology in 100
elderly subjects from the Rush Memory and Aging Project and the Religious Orders Study. First, to validate the information
contained in postmortem MRI data, we tested the hypothesis that postmortem hippocampal volume is smaller in subjects
with clinically diagnosed Alzheimer’s disease compared to subjects with mild or no cognitive impairment, as observed in
antemortem imaging studies. Subsequently, the relations of postmortem hippocampal volume to AD pathology, Lewy
bodies, amyloid angiopathy, gross infarcts, microscopic infarcts, and hippocampal sclerosis were examined. It was
demonstrated that hippocampal volume was smaller in persons with a clinical diagnosis of AD compared to those with no
cognitive impairment (P=2.6610
27) or mild cognitive impairment (P=9.6610
27). Additionally, hippocampal volume was
related to multiple cognitive abilities assessed proximate to death, with its strongest association with episodic memory.
Among all pathologies investigated, the most significant factors related to lower hippocampal volume were shown to be
AD pathology (P=0.0018) and hippocampal sclerosis (P=4.2610
27). Shape analysis allowed for visualization of the
hippocampal regions most associated with volume loss for each of these two pathologies. Overall, this investigation
confirmed the relation of hippocampal volume measured postmortem to clinical diagnosis of AD and measures of
cognition, and concluded that both AD pathology and hippocampal sclerosis affect hippocampal volume in old age, though
the impacts of each pathology on the shape of the hippocampus may differ.
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Introduction
Postmortem MRI of the human brain followed by histology can
be used to better understand the neurobiologic basis of in vivo
imaging findings in Alzheimer’s disease (AD) [1,2] and other
conditions [3,4]. Combining antemortem MRI data with histo-
pathologic information requires that the time between imaging
and death is minimized to eliminate changes that may occur in the
brain in the time between the two events [2]. By employing
postmortem MRI, brain changes between imaging and histology
are minimized. Thus, the combination of postmortem MRI and
histology may be a cost effective experimental approach for
investigating the neuropathologic basis of imaging findings in the
elderly. Further enhancing the utility of postmortem MRI in
research on aging is the fact that living elderly patients are often
uncooperative during scans, increasing the chance for bulk head
motion and image artifacts.
The medial temporal lobe (MTL) has been the focus of much
research due to its important role in the development of
dementias, including AD. Several studies have used MRI to
measure the volume of MTL structures, especially the hippo-
campus, in vivo [2,5–12]. These measurements have been
compared across groups of subjects with a clinical diagnosis of
possible or probable AD, mild cognitive impairment (MCI), and
no cognitive impairment (NCI). Typically, lower hippocampal
volumes were shown to be associated with possible or probable
AD and MCI. Fewer studies have examined the MTL using
postmortem MRI [13–17]. A study at 7.0-T found a significant
reduction in the cross-sectional area of the hippocampus in 13
cases of histopathologically confirmed AD versus controls [15]. A
pair of studies found associations of postmortem hippocampal
volume measurements with AD neuropathology [14] and also
with antemortem measures of delayed recall performance [17].
Finally, a study that employed a rating scale of medial temporal
lobe atrophy found a significant link between atrophy, AD, and
other types of neuropathology [16]. However, none of the
aforementioned postmortem studies investigated in detail the
potential effects of several different neuropathologies on the
quantitative volume or shape of the hippocampus using a large
number of MRI and histopathology datasets, limiting their ability
to attribute hippocampal volume loss to AD and not any other
comorbid pathology.
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to reduction of hippocampal volume. Hippocampal sclerosis (HS)
is characterized by severe neuronal loss with gliosis in the cornu
ammonis 1 (CA1) subregion of the hippocampus [18,19].
Interestingly, a recent report alludes to the possibility that the
effect of HS on hippocampal volume may not be noticeable in
subjects who also have a high amount of AD pathology [2].
Therefore, current diagnostic methods may not be able to
distinguish AD from HS in elderly subjects, either on the basis
of hippocampal volume or the patient’s neuropsychological profile
(both conditions involve similar types of dementia) [20,21].
The purpose of this study was two-fold. The first goal was to
verify that postmortem MRI volumetry of the human hippocam-
pus captures useful information related to the subject’s antemor-
tem clinical diagnosis and cognition, and, therefore, may be a
valuable tool for research on aging, despite the changes that occur
in brain tissue as a result of decomposition, extraction from the
cranium, and fixation. Therefore, we tested the hypothesis that the
volume of the hippocampus, assessed with postmortem MR
volumetry, is lower for clinically diagnosed AD subjects compared
to MCI and NCI subjects, and lower for MCI subjects compared
to NCI subjects, as previously demonstrated by in vivo studies
[22,23]. We also tested the hypothesis that hippocampal volume
measured postmortem is positively related to performance in each
of five different cognitive domains (episodic memory, semantic
memory, working memory, perceptual speed, and visuospatial
ability). From in vivo studies, we anticipated a positive relationship
between episodic memory and postmortem hippocampal volume
[11,17,24], which would further corroborate the important role of
postmortem MRI measurements of hippocampal volume. Follow-
ing the initial verification segment of this study, the second goal
was to use postmortem MRI and histopathology to investigate the
relation of hippocampal volume to neuropathologies frequently
occurring in the elderly: AD pathology, Lewy bodies, amyloid
angiopathy, gross infarcts, microscopic infarcts, and HS pathology.
We expected postmortem hippocampal volume to be most affected
by AD and HS, with a smaller effect related to amyloid angiopathy
[2]. Shape analysis based on spherical harmonics was also
employed to visualize potential differences in the shape and size
of the hippocampus in the presence of different pathologies. The
unique combination of postmortem MRI volumetry and histology
employed in this study allowed us to investigate correlates of
hippocampal structural changes based on reliable measures of
different types of neuropathology that are common in old age.
Methods
Ethics Statement
Cerebral hemispheres were obtained from deceased elderly
subjects who were participants in either of two longitudinal
clinical-pathologic studies of aging: the Rush University Memory
and Aging Project (MAP) and the Religious Orders Study (ROS)
[25]. All participants provided written informed consent and
signed an anatomical gift act. The study was approved by the
Institutional Review Board of Rush University Medical Center. All
clinical investigation has been conducted according to the
principles expressed in the Declaration of Helsinki.
Subjects
During 18 months of investigation, 100 individuals from the
MAP and ROS projects who died with a final diagnosis of AD
(n=44), MCI (n=24), or NCI (n=32) proximate to death were
included in this study. The clinical classification was rendered by
an expert neurologist and was based on the review of all years of
clinical data, including annual neuropsychologic testing that was
reviewed by a board-certified clinical neuropsychologist, and
antemortem clinical evaluations that included a medical history
and neurological examination from all years prior to death
(without access to neuropathologic or postmortem neuroimaging
data). The clinical diagnosis of AD was based on the criteria of the
joint working group of the National Institute of Neurological and
Communicative Disorders and Stroke and the Alzheimer’s Disease
and Related Disorders Association (NINCDS/ADRDA) as
previously described [26]. The clinical diagnosis of MCI referred
to persons who had cognitive impairment but did not meet clinical
criteria for dementia [27,28]. Since clinical diagnoses of MCI and
AD for both the ROS and MAP cohorts were made according to
identical criteria by the same group of investigators, data was
merged for all analyses [29].
Assessment of Cognitive Performance
The two longitudinal studies (MAP and ROS) have 19 cognitive
tests in common. From those, the Mini-Mental State Examination
(MMSE) is used for descriptive purposes, and one other test, the
complex ideas auditory comprehension subtest from the Boston
Diagnostic Aphasia Exam, is only used in diagnostic classification.
The remaining 17 tests assess a broad range of cognitive abilities.
The scores from individual tests are converted to z-scores based on
the mean and standard deviation at baseline, and are combined to
obtain measures of five cognitive domains. Briefly, episodic
memory is evaluated with seven tests including immediate and
delayed recall of story A from Logical Memory and of the East
Boston Story, and Word List Memory, Recall, and Recognition
from the Consortium to Establish a Registry for AD (CERAD).
Semantic memory is assessed with three tests including a 15-item
version of the Boston Naming Test, Verbal Fluency, and a 10-item
reading test. Working memory is also assessed with three tests,
including Digit Span Forward and Backward and Digit Ordering.
There are two tests of perceptual speed, including Symbol Digit
Modalities Test, and Number Comparison. Finally, there are two
tests of visuospatial ability, including a 15-item version of
Judgment of Line Orientation and a 9-item version of Standard
Progressive Matrices. Also, a global cognitive score is formed as a
composite of all 17 test scores. Details of the cognitive tests and the
use of combined measures from both cohorts have been previously
described [25,30,31].
Brain Hemisphere Preparation
After a subject’s death, an autopsy technician removed the brain
and dura from the calvarium by severing the cranial nerves and
the spinal cord at the level of the foramen magnum. Immediately
following removal of the intact brain, the cerebrum was separated
from the cerebellum and brainstem by cutting through the
cerebral peduncles rostrally to the mammillary bodies. The
cerebrum was then divided into left and right hemispheres by
bisecting the corpus callosum. The hemisphere with visible
pathology was selected for imaging. If both hemispheres had
similar amounts of visible pathology or no visible pathology, the
selection was arbitrary. The chosen hemisphere was immersed in
phosphate-buffered 4% formaldehyde solution (prepared from
paraformaldehyde) and refrigerated at 4uC in a sealed plastic
container within 30 minutes after removal from the skull. While in
storage, the 4% formaldehyde solution was changed weekly.
Image Acquisition
Scans took place, on average, after 62 days of fixation (range
22–200). All scans were performed using a 3.0-T GE MRI scanner
(General Electric, Waukesha, WI), with the hemisphere immersed
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acrylic container. Since high spatial resolution MRI scans were
performed in this study, appropriate measures were taken to
reduce the transmission of vibrations from the MRI scanner to the
brain hemispheres. Specifically, the hemispheres were gently
anchored in place using netting, and the acrylic container did not
make direct contact with the vibrating scanner due to the use of a
specially designed bridge apparatus [32]. A 2D fast spin-echo
sequence with two echo times was used to acquire proton density
weighted (PD-weighted) and T2-weighted images, in sagittal slices
through the hemispheres, using the following parameters:
TR=3.6 s, TE1=13.0 ms, TE2=52.0 ms, echo-train length=6,
FOV=16 6 16 cm, slice thickness=1.5 mm, acquisition ma-
trix=2566256 zero-padded to 5126512, acquired 6 times and
averaged (NEX=6). The total scan time was 31 minutes.
Image Analysis
A single operator, blinded to all cognitive data and diagnostic
classifications, outlined the hippocampal formation in every T2-
weighted sagittal slice for each hemisphere, to generate a 3D
region of interest (ROI), using landmarks that have been described
previously [33]. The sagittal plane was used as the primary ROI
selection view because of its superior in-plane resolution
(0.62560.625 mm
2 originally and 0.312560.3125 mm
2 after
zero-filling in k-space), and the coronal and axial views were
referenced as necessary to confirm landmark position. The
intraobserver reliability of this ROI selection method was assessed
using the union overlap metric (intersection of two ROIs divided
by their union) in a subsample of 30 hippocampi which were
outlined twice by the same observer. The hippocampal ROI
included all subdivisions of the cornu ammonis (CA), the dentate
gyrus, and the subiculum (Fig. 1). The volume of each ROI was
calculated by multiplying the number of voxels within the ROI by
a volume of 0.146 mm
3 per voxel. The volume of the entire
hemisphere was calculated using a similar procedure, but with
automatic rather than manual segmentation methods.
Neuropathological Diagnosis
Following imaging, the cerebral hemisphere was placed in a
Plexiglas jig and cut coronally into 1-cm thick slabs. Slabs
underwent complete macroscopic evaluation and dissection of
diagnostic blocks, including midfrontal, middle temporal, inferior
parietal cortex, entorhinal cortex, hippocampus, anterior basal
ganglia, anterior thalamus, and midbrain, including substantia
nigra. These regions were embedded in paraffin, cut into sections,
and mounted on glass slides. Brain autopsy procedures have been
described previously [34,35].
Neuropathologic diagnoses were made by a board-certified
neuropathologist blinded to age and all clinical data (JAS).
Bielschowsky silver stain was used to visualize neuritic plaques
and neurofibrillary tangles in the frontal, temporal, parietal,
entorhinal cortex, and the hippocampus. A neuropathologic
diagnosis of low, intermediate, or high likelihood AD was made
based on the Braak score for neurofibrillary pathology and the
CERAD estimate of neuritic plaques, as recommended by the
NIA-Reagan criteria [36]. Details of the pathologic diagnoses of
AD have been described previously [34,35]. In this study, the
NIA-Reagan score was transformed into a dichotomous variable
by forming one group from the no AD and low likelihood subjects
(non-AD) and another group from the intermediate and high
Figure 1. A typical three-dimensional region of interest created by manually outlining the hippocampal formation in consecutive
T2-weighted sagittal images of a human cerebral hemisphere. Image A corresponds to the most lateral slice and image I to the most medial
slice. The hemisphere remained immersed in formaldehyde solution during the MRI scan. In-plane resolution was 0.312560.3125 mm
2 after zero-
padding of the k-space acquisition matrix.
doi:10.1371/journal.pone.0026286.g001
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antibodies to alpha-synuclein [34] and were classified as nigral,
limbic, or neocortical based on recommended guidelines [37].
Cerebral amyloid angiopathy (CAA pathology) was assessed on
20 micron paraffin-embedded sections from five brain regions:
four neocortical regions comprising the midfrontal (Brodmann
area, BA, 46/9), inferior temporal (BA20), angular gyrus (BA39),
and calcarine cortices (BA17), and one medial temporal region,
the hippocampus (BA24). Sections were stained with antibodies to
amyloid ß protein (Clone 6F/3D, M 0872, DAKO, 1:100; or
10D5, courtesy of Elan pharmaceuticals) using a standard protocol
[38,39]. We used a semiquantitative grading system from 0 (none)
to 5 (most severe) for each region and computed the average for
the overall brain. For analyses, scores of less than 0.5 were
classified as minimal or no CAA, scores between 0.5 and 2.5 were
classified as mild to moderate CAA, and scores above 2.5 were
classified as moderately severe to very severe CAA [39]. The brain
and slabs were examined for cerebral infarcts (infarcts visualized
by the naked eye) as previously described [37]. For analyses, we
classified cases according to the number of gross chronic (old)
infarcts: none, only one, or more than one. Microscopic infarcts
(defined as infarcts seen microscopically but not macroscopically)
were identified on 6-micron hematoxylin and eosin-stained routine
sections [40]. Cases were classified according to the number of
chronic microscopic infarcts: none, only one, or more than one.
HS was assessed on 6 micron sections of hippocampus and was
defined as substantial neuronal loss and gliosis including the CA1
sector.
Statistical Analysis
Analysis of covariance (ANCOVA) was used to test for
differences in hippocampal volume (dependent variable) across
the clinically diagnosed AD, MCI, and NCI groups. The following
covariates were also examined: total hemisphere volume, age, sex,
education, hemisphere side (left or right hemisphere), specimen
source (MAP or ROS), the duration between death and immersion
in formaldehyde (postmortem interval to fixation, PMIf), the
duration between death and MRI (postmortem interval to
imaging, PMIi), and lag between last cognitive exam and death.
The covariates that were not significant were removed one by one
such that all of the parameters remaining in the final ANCOVA
model were significant. We used P,0.05 as the criterion for
statistical significance in these and all other statistical tests
throughout the study.
To evaluate the relation of postmortem hippocampal volume to
antemortem cognition, we used multiple regression analysis with
volume as the dependent variable and cognitive score as the
independent variable. Separate regressions were first carried out
for the global cognitive score and each of the five individual
domain scores (episodic, semantic, and working memory,
perceptual speed, and visuospatial ability), while controlling for
the previously mentioned covariates. Subsequently, all five domain
scores were entered in a combined regression model to determine
which were the most significant predictors of hippocampal
volume. In the regression models, non-significant terms were
eliminated one by one until all of the remaining model coefficients
were significant.
ANCOVA was then used to examine the relations of AD and
other common types of pathology to hippocampal volume. Each
type of pathology was investigated individually at first, while
controlling for the previously mentioned covariates. Subsequently,
all types of pathology were entered in a combined model in order
to determine which were the most significant predictors of
hippocampal volume. In these ANCOVA models, non-significant
factors were eliminated from the model one by one until all of the
remaining factors were significant.
The Spherical Harmonic-Point Distribution Model (SPHARM-
PDM) Toolbox [41] was employed for analysis of the hippocampal
shape associated with each pathology that was found to be
significantly related to hippocampal volume. A three-dimensional
mesh (a networked collection of points) was first produced to
represent the surface of each hippocampal ROI. All left
hippocampi were mirrored to appear as right. A spherical
parameterization was then computed for each mesh. Group
differences in the distances between corresponding points on the
surface meshes were detected using the Hotelling T
2 metric [42].
In controlling for multiple comparisons, a false discovery rate of
5% was accepted.
Results
MAP and ROS subjects and hemispheres
Demographic information, clinical diagnoses, and other char-
acteristics for the 65 MAP subjects and 35 ROS subjects are
shown in Table 1. The average age at death for all 100 subjects
was 87.866.0 years (mean 6 s.d.). MAP subjects were older than
their ROS counterparts at the time of death (3.9% older,
P=0.0065) and had fewer years of education (18% fewer,
P=2.4610
25), but no other statistically significant differences
between the groups’ demographic characteristics, including
incidence of clinically diagnosed MCI and AD, or neuropatho-
logically diagnosed AD, were observed. The time between a
subject’s last cognitive examination and death averaged 2496142
days (mean 6 s.d.) for the 100 hemispheres in this study, and was
not statistically different between the MAP and ROS hemispheres.
The PMIf averaged 7.264.5 hours (mean 6 s.d.) for the 100
hemispheres in this study and was not statistically different
between the MAP and ROS hemispheres. The PMIi averaged
62636 days, and was significantly shorter for MAP hemispheres
compared to ROS hemispheres (22% shorter, P=0.032, Table 1).
This difference was due to delays in transportation of some ROS
hemispheres from satellite autopsy locations to the central imaging
site.
NCI, MCI, and AD subjects and hemispheres
Characteristics of NCI, MCI, and AD subjects are shown in
Table 2. Among the three groups, there were no significant
differences in age, sex, education, hemisphere side, PMIf, PMIi,o r
the time between the last cognitive exam and death, according to
simple ANOVA with Tukey’s honestly significant difference post
hoc test accounting for multiple comparisons. The AD group was
characterized by significantly lower MMSE scores and cognitive
domain z-scores than the MCI and NCI groups (P,10
28 for all).
In addition, the MMSE and cognitive domain z-scores were all
lower for the MCI group compared to the NCI group, but this
difference only reached the level of statistical significance for the
perceptual speed domain (P=0.040). Total hemisphere volume
was significantly smaller in the MCI group compared to the NCI
group (8% smaller, P=0.012). The hemisphere volume was also
smaller in the AD group compared to NCI (7% smaller,
P=0.015).
Relation of hippocampal volume measured postmortem
to clinical diagnosis
The intraobserver reliability of the ROI selection technique was
high, as evidenced by the 88% union overlap that was calculated
using a subsample of 30 subjects. By ANCOVA, postmortem
hippocampal volume was significantly lower in the group of
Correlates of Hippocampal Atrophy
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(MAP) and the Religious Orders Study (ROS) included in this work.
Characteristics MAP ROS All
N 6 53 51 0 0
Age at death, y (SD)
a89.0 (5.7) 85.6 (5.9) 87.8 (6.0)
Male, n (%) 24 (37%) 12 (34%) 36 (36%)
Education, y (SD)
b15.0 (3.2) 18.3 (4.1) 16.2 (3.9)
Height, in. (SD) 65.0 (3.8) 64.4 (4.8) 64.8 (4.2)
Left hemisphere, n (%) 35 (54%) 17 (49%) 52 (52%)
Mini-mental state examination score proximate to death (SD) 20.6 (9.1) 20.7 (10.2) 20.6 (9.4)
Global cognition z-score (SD) 20.99 (1.21) 20.89 (1.31) 20.95 (1.24)
Hippocampal volume, cm
3 (SD) 2.67 (0.59) 2.64 (0.63) 2.66 (0.60)
Postmortem interval to fixation, h (SD) 6.8 (4.2) 8.1 (5.0) 7.2 (4.5)
Postmortem interval to imaging, days (SD)
c56 (29) 72 (44) 62 (36)
Days between last cognitive exam and death (SD) 252 (140) 243 (148) 249 (142)
Clinical diagnosis, n (%) - - -
–No cognitive impairment 22 (34%) 10 (29%) 32 (32%)
–Mild cognitive impairment 14 (21%) 10 (29%) 24 (24%)
–Alzheimer’s disease 29 (45%) 15 (43%) 44 (44%)
Neuropathological diagnosis of Alzheimer’s disease, n (%) - - -
–No 33 (51%) 18 (51%) 51 (51%)
–Yes 32 (49%) 17 (49%) 49 (49%)
aSignificantly different from ROS (P=0.0065).
bSignificantly different from ROS (P=2.4 610
25).
cSignificantly different from ROS (P=0.032).
doi:10.1371/journal.pone.0026286.t001
Table 2. Selected characteristics of groups of subjects with no cognitive impairment (NCI) and clinical diagnoses of mild cognitive
impairment (MCI) and Alzheimer’s disease (AD).
Characteristics NCI MCI AD
N3 2 2 4 4 4
Age at death, y (SD) 86.4 (6.1) 87.8 (7.3) 88.8 (4.9)
Male, n (%) 11 (34%) 6 (25%) 19 (43%)
Education, y (SD) 15.5 (3.7) 16.0 (4.5) 16.8 (3.6)
Height, in. (SD) 65.2 (3.8) 63.7 (5.0) 65.1 (3.9)
Left hemisphere, n (%) 17 (53%) 12 (50%) 23 (52%)
Days between last cognitive exam and death (SD) 263 (146) 270 (152) 227 (133)
MMSE proximate to death (SD) 28.0 (1.7) 25.5 (4.0)
d12.6 (8.7)
Global cognition (SD) 0.08 (0.48) 20.37 (0.59)
d22.03 (1.01)
Episodic memory (SD) 0.25 (0.45) 20.23 (0.88)
d22.08 (1.07)
Semantic memory (SD) 0.05 (0.58) 20.22 (0.73)
d22.04 (1.65)
Working memory (SD) 0.07 (0.74) 20.37 (0.68)
d21.57 (1.12)
Perceptual speed (SD) 20.28 (0.84)
e20.91 (0.87)
d22.21 (1.03)
Visuospatial ability (SD) 20.04 (0.48) 20.37 (0.59)
d22.02 (1.01)
Hippocampal volume, cm
3 (SD) 3.01 (0.45) 2.85 (0.50)
f2.30 (0.55)
Total hemisphere volume, cm
3 (SD)
g428.5 (45.4) 392.9 (44.5) 398.9 (44.4)
Postmortem interval to fixation, h (SD) 7.4 (4.8) 8.4 (5.1) 6.5 (3.9)
Postmortem interval to imaging, days (SD) 64 (40) 58 (34) 62 (34)
dSignificantly different from NCI and from MCI (P,10
28 for both).
eSignificantly different from NCI (P=0.040).
fSignificantly different from NCI (P=2.6 610
27) and from MCI (P=9.6 610
27).
gSignificantly different from MCI (P=0.012) and from AD (P=0.015).
doi:10.1371/journal.pone.0026286.t002
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lower, P=9.6610
27) and NCI (21% lower, P=2.6610
27) groups
(Fig. 2). There was no significant difference in hippocampal
volume between the MCI and NCI groups (P=0.96). Similar
findings resulted from ANCOVA that did not control for
hemisphere volume. Similar findings also resulted from ANCOVA
in which subject height, which others have used as a surrogate for
total intracranial volume [24], replaced the hemisphere volume
covariate (total intracranial volumes were not available since the
brain hemispheres were not imaged in situ).
Relation of hippocampal volume measured postmortem
to cognition
The relation of hippocampal volume measured postmortem to
level of cognition was investigated next. Linear regressions
revealed a statistically significant positive relationship between
hippocampal volume and global cognition (Table 3, Fig. 3).
Separate linear regressions also revealed significant positive
relationships between hippocampal volume and each of the five
individual cognitive domains: episodic memory, semantic memo-
ry, working memory, perceptual speed, and visuospatial ability
(Table 3, Fig. 3). When all five individual cognitive scores were
entered in a single combined regression, only episodic memory
retained a statistically significant relation to hippocampal volume.
After removal of those terms that were not significant, this
combined model became equivalent to the individual regression of
hippocampal volume against episodic memory (Table 3). Results
were similar when hemisphere volume was not included in the
regressions and also when subject height replaced hemisphere
volume in the regressions.
Relation of hippocampal volume measured postmortem
to neuropathology
We next examined the relation of hippocampal volume to AD
and other neuropathologies that are frequently found in the aging
human brain. When an individual ANCOVA was executed for
each type of pathology, HS showed the strongest relation with
hippocampal volume, both in terms of magnitude (20.80 cm
3)
and its statistical significance (P=1.2610
27) (Table 4). AD
pathology also had a large and highly significant relation with
hippocampal volume (20.38 cm
3, P=4.1610
24). The relation of
moderately severe to very severe amyloid angiopathy was also
significant (20.41 cm
3, P=0.0020). There was a marginally
significant relation of hippocampal volume with both nigral
(20.52 cm
3, P=0.059) and limbic (20.38 cm
3, P=0.051) Lewy
bodies.
All types of neuropathology measured in this study were then
entered in a combined ANCOVA model. After the least significant
factors were eliminated from the model one by one, AD pathology
(20.29 cm
3, P=0.0018) and HS (20.73 cm
3, P=4.2610
27) were
the only pathologies that retained statistically significant relations
to hippocampal volume (Table 5). Dichotomizing the Lewy body,
gross infarct, and microscopic infarcts factors (pathology present or
not present, regardless of quantity) also did not substantially alter
the results, nor were these factors found to be significant.
Removing hemisphere volume from the analysis did not
substantially alter the results, nor did replacing hemisphere
volume with subject height.
The strong associations between hippocampal volume, AD, and
HS pathology were investigated further. First, an interaction factor
between AD and HS was added to the ANCOVA model. The
addition of this term did not substantially alter the results, nor was
the interaction factor found to be significant in the ANCOVA
model. Next, subjects were compared by groups that had been
histopathologically diagnosed as having neither AD nor HS, AD
but not HS, HS but not AD, or both AD and HS (Table 6). AD
subjects (without HS) were shown by ANOVA (no correction for
hemisphere volume or any other parameters) to have hippocampal
volumes that were approximately 0.35 cm
3 smaller than the non-
AD, non-HS subjects (P=0.0068). AD subjects with concomitant
HS had hippocampal volumes that were 0.74 cm
3 smaller than the
AD-only subjects (P=5.8610
24) and 1.09 cm
3 smaller than the
non-AD, non-HS subjects (P=1.5610
27). Similarly, HS-only
subjects had hippocampal volumes that were 0.72 cm
3 smaller
than the AD-only subjects (P=0.034) and 1.07 cm
3 smaller than
the non-AD, non-HS subjects (P=4.1610
24).
We also considered the possibility that the larger association of
HS with hippocampal volume (compared to that of AD with
hippocampal volume) could have been due to the cases of HS
being pathologically more severe than the cases of AD
encountered in this study (see cognitive scores of HS versus AD
Figure 2. Box plot of hippocampal volumes for clinically
diagnosed Alzheimer’s disease, mild cognitive impairment,
and no cognitive impairment subjects. The horizontal line through
each box indicates the median. The ends of each box indicate the 25
th
and 75
th percentile locations, and the lines indicate the range of the
data. Hippocampal volume was significantly smaller in Alzheimer’s
disease than in cases of mild cognitive impairment or no cognitive
impairment.
doi:10.1371/journal.pone.0026286.g002
Table 3. Coefficient values for linear regression models of
postmortem hippocampal volume as a function of global
cognition and other covariates, and the corresponding P-
values.
Factor Regression Coefficient P-value
Global cognition 0.20 1.8610
26
Episodic memory 0.20 4.0610
28
Semantic memory 0.15 1.3610
25
Working memory 0.14 0.0024
Perceptual speed 0.18 2.4610
25
Visuospatial ability 0.10 0.022
Regression coefficients significantly different from zero in boldface.
All models adjusted for total hemisphere volume, age, sex, education,
hemisphere side, specimen source, the postmortem interval to fixation, the
postmortem interval to imaging, and time between last cognitive exam and
death.
doi:10.1371/journal.pone.0026286.t003
Correlates of Hippocampal Atrophy
PLoS ONE | www.plosone.org 6 October 2011 | Volume 6 | Issue 10 | e26286subjects, Table 6). We conducted further analyses to investigate
this. In the first approach, we added to the ANCOVA model a
cognition term (either MMSE score, global cognition score, or
episodic memory score), intended to serve as a proxy for
pathologic severity of either HS or AD. The ANCOVA results
were similar regardless of which score was used as the cognition
term. Specifically, the association of HS with volume remained
significantly larger than the association of AD with volume. For
the second approach, in order to simulate the groups of HS and
AD subjects having the same mean cognitive scores (cognition was
again used as a proxy for pathologic severity of HS and AD), the
postmortem hippocampal volume measurements of AD subjects
were extrapolated, based on the observed relation between
hippocampal volume and measures of cognition in AD subjects.
This correction factor accounted for a maximum of 0.18 cm
3,o r
approximately 25%, of the difference in hippocampal volume
between HS and AD subjects. Finally, in the third approach for
equalizing the pathologic severity of the HS and AD groups, only
the most severe cases of AD, meeting the NIA-Reagan criteria for
high likelihood of AD, were included in the ANCOVA. In this
analysis, the association of hippocampal volume with AD became
stronger (20.43 cm
3), as expected, but was still substantially
weaker than the association of hippocampal volume with HS
(20.75 cm
3)( P=1.6610
27).
Hippocampal shape analysis in the presence of different
neuropathologies
For hippocampi affected by AD only (not HS), the difference in
shape compared to hippocampi unaffected by either disease was
greatest in the medial-lateral direction, primarily due to inward
deformations of the surface near the head and tail of the
Figure 3. Plots of the hippocampal volume as a function of the z-score for global cognition, episodic memory, semantic memory,
working memory, perceptual speed, and visuospatial ability. Clinical diagnosis for each subject is indicated by marker type.
doi:10.1371/journal.pone.0026286.g003
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cases of AD (meeting the NIA-Reagan criteria for high likelihood
of AD) were included in the analysis, a similar pattern of shape
difference was observed (Fig. 4B), but the inward deformations of
the surface mesh were even larger in magnitude and significance.
For hippocampi affected by HS (9 also with AD, 4 without AD),
the surface mesh was deformed inward in excess of 1 mm at many
locations throughout the structure, when compared to hippocampi
unaffected by either condition (Fig. 4C). The superior surface of
the hippocampal body was relatively preserved compared to other
regions. The overall differences in shape between the control
hippocampi, those affected by AD, and those affected by sclerosis
are visible in Figure 5. Results were essentially the same when
hemisphere volume was not accounted for in the shape analysis.
Discussion
Postmortem MRI ensures that brain changes are minimized
between imaging and histology, and therefore may be particularly
useful in directly assessing the neuropathologic correlates of
structural MRI changes in the hippocampus in the elderly.
However, the value of the information collected with postmortem
MRI has not been thoroughly assessed. Therefore, the current
study first tested the hypothesis that hippocampal volume, when
measured with MRI postmortem, is linked to clinical diagnosis of
AD, as shown by studies that employed in vivo (antemortem)
MRI. We then tested the hypothesis that hippocampal volume
measured postmortem is positively related to antemortem
cognitive performance, as shown by in vivo MRI studies. After
these validation steps, we proceeded to use postmortem MRI and
histology in an investigation of the neuropathologic correlates of
structural MRI changes in the hippocampus in the elderly.
Results showed that hippocampal volumes measured postmor-
tem were significantly lower in clinically diagnosed AD patients
compared to MCI or NCI subjects, consistent with hippocampal
atrophy in clinically diagnosed AD patients. Similar results were
presented in most previously published reports that employed
MRI volumetry of the human hippocampus in vivo
[2,6,8,9,14,43]. The current work also indicated that the
hippocampal volume for MCI subjects was not significantly
different than that of NCI subjects. However, other published
research measured significant differences in hippocampal volumes
Table 4. Effects of different types of neuropathology on hippocampal volume, assessed individually using analysis of covariance,
and the corresponding P-values.
Type of Pathology Number of Subjects
Association with Hippocampal
Volume (cm
3) P-value
Alzheimer’s (NIA criteria) 49 20.38 4.1610
24
Lewy bodies - - -
–Nigral 4 20.52 0.059
–Limbic 9 20.38 0.051
–Neocortical 8 20.29 0.15
Amyloid angiopathy - - -
–Mild to moderate 36 20.01 0.94
–Moderately severe to very severe 35 20.41 0.0020
Gross infarcts - - -
–Only one 16 0.11 0.46
–More than one 11 20.16 0.35
Microscopic infarcts - - -
–Only one 24 20.17 0.19
–More than one 4 20.43 0.13
Hippocampal sclerosis 13 20.80 1.2610
27
Effects significantly different from zero in boldface.
All models adjusted for total hemisphere volume, age, sex, education, hemisphere side, specimen source, postmortem interval to fixation, and postmortem interval to
imaging.
doi:10.1371/journal.pone.0026286.t004
Table 5. Effect of AD pathology and hippocampal sclerosis on hippocampal volume, assessed simultaneously using analysis of
covariance, and the corresponding P-values.
Type of Pathology Number of Subjects Effect on Hippocampal Volume (cm
3) P-value
Alzheimer’s (NIA criteria) 49 20.29 0.0018
Hippocampal sclerosis 13 20.73 4.2610
27
Only statistically significant neuropathologies were included in the final combined analysis of covariance model.
Model adjusted for total hemisphere volume, age, sex, education, hemisphere side, specimen source, postmortem interval to fixation, and postmortem interval to
imaging.
doi:10.1371/journal.pone.0026286.t005
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or questionable dementia [8,22,23,44,45]. This discrepancy may
be due to one or more of the following factors: differences in the
sample sizes; differences in ROI selection techniques; differences
in spatial resolution of the MR images; the fact that the MCI
group of the present study was not restricted to cases of amnestic
MCI; or the fact that in the present study hippocampal volume
was not normalized with intracranial volumes, but instead total
hemisphere volume or height were separately included in the
models as a covariate.
Significant positive relationships between hippocampal volume
and the z-scores in five cognitive domains (episodic, semantic, and
working memory, perceptual speed, and visuospatial ability,
Table 3), as well as in the global cognition domain, were revealed
when each domain was examined separately. Similar findings were
obtained in previously published studies that demonstrated
linkages between in vivo hippocampal volume and a measure of
working memory [17], the Wechsler memory scale, and
performance in the California verbal learning test and the Grober
and Buschke test [11].
The scores for the five cognitive domains investigated here are
known to have a high degree of correlation with each other.
Therefore, the use of a combined regression model was necessary.
When the z-scores from all five cognitive domains were included in
a combined linear regression, hippocampal volume was shown to
be significantly related only to episodic memory. Although in
younger subjects the association of hippocampal volume with
episodic memory is tenuous, many studies involving elderly
subjects have reported a positive and significant relation. This is
possibly because hippocampal volume and episodic memory both
tend to erode in later life [24]. The positive relation of
hippocampal volume to episodic memory found in the current
work is consistent with previous findings since the current study
involved very old subjects.
The finding that hippocampal volume is more strongly related
to episodic memory than other cognitive domains is also consistent
with existing knowledge of hippocampal function. Episodic
memory is very closely linked to the hippocampus, even more so
than semantic memory [46,47]. Contributions to working memory
come not only from the hippocampus, but also from other brain
regions [48,49]. Similarly, perceptual speed [50] and visuospatial
ability [51] have not been wholly attributed to the hippocampus,
so these cognitive domains may not be as strongly related to
hippocampal volume as is episodic memory. As shown by the
association of smaller hippocampal volume with clinical diagnosis
of AD, and also by the relation of hippocampal volume to
cognition (especially in the episodic memory domain), hippocam-
pal volume measured via postmortem MRI captures important
information related to the disease state of the brain.
It was demonstrated that AD pathology had a large and
significant relation to hippocampal volume (Table 5). Other
studies have employed postmortem MRI to examine the relation
between AD pathology and structural changes in the MTL;
however, these studies either had a relatively small number of
Table 6. Selected demographic, clinical, and neuropathologic characteristics of subjects with no histopathologically diagnosed
Alzheimer’s disease (AD) or hippocampal sclerosis (HS), with AD only, with HS only, and with both AD and HS.
Characteristics Non-AD, Non-HS AD HS AD+HS
N4 7 4 0 4 9
Age at death, y (SD) 86.8 (7.0) 88.7 (4.9) 87.7 (7.8) 88.8 (3.3)
Male, n (%) 14 (30%) 18 (45%) 1 (25%) 3 (33%)
Education, y (SD) 15.3 (3.7) 16.8 (4.1) 16.3 (2.9) 18.0 (3.2)
Height, in. (SD) 64.0 (4.3) 65.6 (3.9) 63.3 (4.3) 65.8 (4.0)
Left hemisphere, n (%) 25 (53%) 20 (50%) 3 (75%) 4 (44%)
Mini-mental state examination score (SD) 24.8 (6.0)
h18.4 (10.3)
h12.9 (13.3)
h12.6 (9.1)
Global cognition (SD) 20.39 (0.88)
h21.21 (1.24) 21.69 (1.53)
h,i22.40 (1.19)
Episodic memory (SD) 20.18 (0.98) 21.27 (1.35) 21.51 (1.51) 22.61 (1.02)
Semantic memory (SD) 20.30 (0.98) 21.17 (1.45) 21.77 (2.15) 22.83 (2.25)
Working memory (SD) 20.41 (0.97) 20.89 (1.20) 21.55 (1.43) 21.63 (1.35)
Perceptual speed (SD) 20.82 (1.14) 21.43 (1.23) 22.16 (1.16) 22.61 (0.86)
Visuospatial ability (SD) 20.59 (1.09) 20.89 (1.21) 21.95 (1.86) 21.46 (1.33)
Total hemisphere volume, cm
3 (SD) 409.8 (44.3) 410.8 (47.6) 368.3 (13.8) 391.8 (59.9)
Hippocampal volume, cm
3 (SD) 2.94 (0.51)
h2.59 (0.48)
h,i1.87 (0.40)
h,i1.85 (0.47)
Postmortem interval to fixation, h (SD) 7.7 (5.1) 6.7 (4.1) 6.2 (2.9) 7.9 (3.5)
Postmortem interval to imaging, days (SD) 68 (42) 54 (29) 45 (22) 71 (22)
Days between cognitive exam and death (SD) 253 (144) 243 (129) 72 (60)
j331 (156)
Lewy bodies (any), n (%) 8 (17%) 9 (23%) 1 (25%) 3 (33%)
Amyloid angiopathy, n (%) 1 (2%)
h,j27 (68%) 0 (0%)
h,j7 (78%)
Gross infarcts, n (%) 11 (23%) 14 (35%) 1 (25%) 1 (11%)
Microscopic infarcts, n (%) 12 (26%) 13 (33%) 2 (50%) 1 (11%)
hSignificantly different from Non-AD/Non-HS (P,0.05).
iSignificantly different from AD (P,0.05).
jSignificantly different from HS (P,0.05).
doi:10.1371/journal.pone.0026286.t006
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that may affect hippocampal volume [14,17], or lacked a
quantitative measure of hippocampal volume [16]. The current
study is unique in that it included a relatively large number of
subjects (100) and showed that hippocampal volume measured
using postmortem MRI was smaller in cases of pathologic AD,
even after controlling for other common neuropathologies of
aging.
The number of neurons in the hippocampus is correlated with
its volume, both in control subjects and AD patients [13,52–54].
Therefore, neuronal loss is a plausible etiology of the AD-related
reduction in hippocampal volume observed in this study.
Substantial evidence points to an apoptotic mechanism of cell
death in AD [55,56], possibly spurred on by amyloid beta peptide
toxicity [57]. A necrotic pathway of cell death may also be
involved [58]. Other plausible etiologies of hippocampal atrophy
include loss of axons and dendrites, loss of non-neuronal elements
such as glia and vessels, or other phenomena occurring in
association with neurodegeneration and other age related
pathologies.
HS was shown to have an even larger association with
hippocampal volume than AD pathology. However, based on
cognitive scores, the 13 HS subjects in the current study were more
cognitively impaired than the AD subjects. It follows that the cases
of HS may have been more severe pathologically than the cases of
AD. Therefore, we separately employed three approaches to
account for the potential difference in the pathologic severity of
HS and AD cases in this study – first by including a cognitive score
in the ANCOVA as a proxy for pathologic severity; second by
extrapolating the hippocampal volumes of AD subjects based on
their cognitive scores, again using cognition as a proxy for
pathologic severity; and third by including only the most severe
cases of AD in the analysis. All approaches yielded essentially the
same finding, namely that HS has a substantially greater
association with postmortem hippocampal volume than does
AD, even when the pathologic severity of the HS and AD groups
are equalized to the extent possible.
It has been reported that the effect of HS on hippocampal
volume is larger in subjects with lower amounts of AD pathology
compared to those with higher amounts of AD pathology [2], but
results of the current study do not support this finding, since the
interaction factor between AD and sclerosis was not found to be
significantly different from zero when it was included in the
ANCOVA model. Furthermore, hippocampal volume was nearly
identical between groups of subjects with HS only and those with
HS and concomitant AD pathology (1.87 cm
3 and 1.85 cm
3,
respectively). However, the current study included only 4 HS
subjects that did not have concomitant AD pathology, which
limited the statistical power of this comparison.
Figure 4. Shape analysis of (A) hippocampi affected by
Alzheimer’s disease (AD) and not hippocampal sclerosis (HS)
compared to controls, (B) hippocampi most severely affected
by AD compared to controls, and (C) hippocampi affected by
HS with or without AD compared to controls. The top row of
images contains the superior view of the hippocampus, while the
bottom row contains the inferior view. Within each comparison, the left
side shows a map of the difference in distance between points on the
surface mesh of the first group versus the corresponding points on the
surface mesh of the second group, projected along a unit vector that is
normal to the surface. Thus, red shading shows areas of inward
deformation of the first group relative to the second group, and green
shading shows areas of outward deformation. The right side of each
comparison shows significance maps with color indicating P-value. The
significance maps show regions where points on the surface mesh of
the first group are significantly displaced from the corresponding points
on the surface mesh of the second group in any direction.
doi:10.1371/journal.pone.0026286.g004
Figure 5. The average shapes of hippocampi affected by
neither Alzheimer’s disease (AD) or hippocampal sclerosis (HS)
(N=47), AD only (N=40), and HS (N=13, 9 with AD and 4 with
HS only), viewed from the superior direction. The dashed line is
the outline of the control hippocampal surface mesh.
doi:10.1371/journal.pone.0026286.g005
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microscopic infarcts showed marginally significant associations
with reduced hippocampal volume, while severe amyloid angiop-
athy showed a significant association. However, none of these
associations were found to be statistically significant in a combined
model that included multiple neuropathologies. A weak effect of
amyloid angiopathy on hippocampal volume has been reported
[2]. Another study reported an association of smaller hippocampal
volume with Lewy bodies, but the association of volume with AD
was greater [59]. There are several possible explanations for these
minor discrepancies. First, there were differences in statistical
power across studies (Lewy bodies were only found in 21 of the
100 hemispheres in the current study, for example). Second, there
may have been differences in the methods used for quantification
of neuropathology and ROI selection, as well as differences in
spatial resolution in the MR images. Third, the use of antemortem
MRI in the referenced studies [2,59] may have allowed for brain
changes to occur between imaging and histology. Finally, the use
of hippocampal volume measurements that were normalized with
intracranial volumes in the referenced studies [2,59] is different
from the normalization technique used in the current study.
The current study used shape analysis in order to visualize the
pattern of hippocampal shape in elderly subjects that have been
histopathologically evaluated. Several studies have used shape
analysis in living subjects who were clinically diagnosed with AD
or MCI. One such study found a link between inward deformation
of the hippocampal surface, primarily in the CA1 subregion, and
diminished delayed recall ability in MCI and AD subjects [60].
Other studies showed that subjects with AD-type dementia had
greater atrophy primarily, but not exclusively, in the CA1
subregion compared to non-demented controls [61–63]. It has
also been shown that this inward variation of the hippocampal
surface in the CA1 subregion potentially occurs early enough to
predict a non-demented individual’s likelihood of converting to
AD-type dementia [64]. In the current study, the observed
hippocampal shape in histopathologically confirmed cases of AD
was similar to the results of the aforementioned studies that relied
only on clinical diagnostic information for classification of subjects.
The statistically significant inward deformation that was detected
on the lateral side of the hippocampus and in the hippocampal
head and tail (Fig. 4A and 4B) probably corresponds to volume
loss primarily in the CA1 subdivision, consistent with the high level
of AD pathology that is frequently found in this particular region
[52,65,66]. Although AD pathology can be found in all
subdivisions of the hippocampus depending on the stage of the
disease, the fact that CA1 is affected first and most predominantly
[65,66] is probably the reason why neuroimaging studies that
employ hippocampal shape analysis most commonly detect
volume loss in CA1 [60–63].
The observed pattern of inward deformation of the surface
mesh associated with HS is also consistent with existing knowledge
of that condition. We observed large inward deformations along
the medial and inferior surfaces of the hippocampal body (Fig. 4C),
approximately corresponding to the CA1 subregion and subicu-
lum, frequently reported as exhibiting the highest degree of
neuronal loss and gliosis in HS [18,19]. Furthermore, the CA2 and
CA3 subregions are typically spared of sclerotic pathology [19],
and in the current study, the relatively preserved region on the
superior surface of the hippocampus appears to be at the
approximate location of CA2 and CA3 (Fig. 4C).
It was not the goal of this study to systematically investigate the
effectiveness of hippocampal volume or shape as an early
biomarker of AD. Nevertheless, results show that raw hippocam-
pal volume cannot be used alone as a tool for early diagnosis of
AD, given that HS is also associated with hippocampal volume
reduction. Imaging of brain structure (e.g. hippocampal shape),
function, and physiology may need to be combined to achieve
accurate AD diagnosis during life.
The current study has certain limitations. First, intracranial
volumes were not available for hippocampal volume normaliza-
tion; instead, hemisphere volume was included as a covariate in
the models. As a result of this practice, it is conceivable that
reductions in hippocampal volume may have been masked by
proportional decreases in total hemisphere volume. For this
reason, we repeated the entire analysis without accounting for
hemisphere volume and found that the results were essentially
unchanged. We also repeated the analysis with subject height
replacing hemisphere volume as a covariate in the models [24],
and again found no substantial differences in the results. Notably,
AD and HS were still the only two types of pathology that showed
a significant association with hippocampal volume. A second
limitation of the current study stems from the fact that subjects
with histories of epilepsy or seizures were not specifically excluded
from the group of 13 subjects with HS. The concern lies in the
possibility that idiopathic HS observed in elderly subjects
represents a different pathological phenomenon than HS accom-
panied by seizures. Four of the 13 subjects had taken anti-
convulsive medication at some point in their lives, though we have
no record of epilepsy diagnosis.
This study demonstrated that, despite the tissue changes that
occur as a result of extraction of the brain from the cranium, tissue
decomposition, and fixation, and also despite the lack of
intracranial volume measurements for volume normalization
purposes, postmortem MRI volumetry of the human hippocampus
captures useful information about the antemortem cognitive,
clinical, and neuropathological state of brain tissue. Therefore,
postmortem MRI in combination with histology may allow direct
assessment of the neuropathologic correlates of hippocampal
volume in the elderly. Specific findings revealed a statistically
significant link between reduced postmortem hippocampal volume
and clinical diagnosis of AD, in agreement with similar studies that
employed traditional antemortem MRI. Positive relationships
were also detected between hippocampal volume measured
postmortem and antemortem cognition, particularly in the
episodic memory domain, which is known to be highly associated
with hippocampal function. Of the neuropathologies that were
investigated, AD and HS had the strongest association with
hippocampal volume. The hippocampal shapes related to AD and
HS were consistent with existing knowledge regarding the
hippocampal regions susceptible to volume loss in those diseases.
Future investigations will utilize different types of MR contrast to
extract additional information from postmortem brain tissue
collected in the MAP and ROS longitudinal studies of aging.
Acknowledgments
The authors thank Ashish Tamhane, for his help with data entry; Sunil
Vasireddi, for his help with conducting scans; and Veronica Flores, Ryan
Johnson, Catherine Ulman, Dennis Brown, Kenneth Simon, Debra
Magnuson, Kefiloe Tsotetsi, and Karen Skish, for preparing the brain
hemispheres. We also thank the participants in the Rush Memory and
Aging Project and the Religious Orders Study.
Author Contributions
Conceived and designed the experiments: RD DB JS KA. Performed the
experiments: RD JS. Analyzed the data: RD JS. Contributed reagents/
materials/analysis tools: RD DB JS KA. Wrote the paper: RD DB JS KA.
Correlates of Hippocampal Atrophy
PLoS ONE | www.plosone.org 11 October 2011 | Volume 6 | Issue 10 | e26286References
1. Gouw AA, Seewann A, Vrenken H, van der Flier WM, Rozemuller JM, et al.
(2008) Heterogeneity of white matter hyperintensities in Alzheimer’s disease:
post-mortem quantitative MRI and neuropathology. Brain 131: 3286–3298.
2. Jagust WJ, Zheng L, Harvey DJ, Mack WJ, Vinters HV, et al. (2008)
Neuropathological basis of magnetic resonance images in aging and dementia.
Ann Neurol 63: 72–80.
3. Fazekas F, Kleinert R, Roob G, Kleinert G, Kapeller P, et al. (1999)
Histopathologic analysis of foci of signal loss on gradient-echo T2*-weighted MR
images in patients with spontaneous intracerebral hemorrhage: evidence of
microangiopathy-related microbleeds. Am J Neuroradiol 20: 637–642.
4. Seewann A, Kooi E-J, Roosendaal SD, Barkhof F, van der Valk P, et al. (2009)
Translating pathology in multiple sclerosis: the combination of postmortem
imaging, histopathology and clinical findings. Acta Neurol Scand 119: 349–355.
5. Jack CR, Jr., Petersen RC, Xu YC, Waring SC, O’Brien PC, et al. (1997)
Medial temporal atrophy on MRI in normal aging and very mild Alzheimer’s
disease. Neurology 49: 786–794.
6. Arfanakis K, Gui M, Tamhane AA, Carew JD (2007) Investigating the medial
temporal lobe in Alzheimer’s disease and mild cognitive impairment, with
Turboprop diffusion tensor imaging, MRI-volumetry, and T2-relaxometry.
Brain Imaging Behav 1: 11–21.
7. Laakso MP, Partanen K, Soininen H, Lehtovirta M, Hallikainen M, et al. (1996)
MR T2 relaxometry in Alzheimer’s disease and age-associated memory
impairment. Neurobiol Aging 17: 535–540.
8. Wolf H, Grunwald M, Kruggel F, Riedel-Heller SG, Angerho ¨fer S, et al. (2001)
Hippocampal volume discriminates between normal cognition; questionable and
mild dementia in the elderly. Neurobiol Aging 22: 177–186.
9. van de Pol LA, Hensel A, Barkhof F, Gertz HJ, Scheltens P, et al. (2006)
Hippocampal atrophy in Alzheimer disease: Age matters. Neurology 66:
236–238.
10. Jack CR, Jr., Dickson DW, Parisi JE, Xu YC, Cha RH, et al. (2002)
Antemortem MRI findings correlate with hippocampal neuropathology in
typical aging and dementia. Neurology 58: 750–757.
11. Deweer B, Lehe ´ricy S, Pillon B, Baulac M, Chiras J, et al. (1995) Memory
disorders in probable Alzheimer’s disease: the role of hippocampal atrophy as
shown with MRI. J Neurol Neurosurg Psychiatry 58: 590–597.
12. Jernigan TL, Archibald SL, Fennema-Notestine C, Gamst AC, Stout JC, et al.
(2001) Effects of age on tissues and regions of the cerebrum and cerebellum.
Neurobiol Aging 22: 581–594.
13. Bobinski M, de Leon MJ, Wegiel J, Desanti S, Convit A, et al. (2000) The
histological validation of post mortem magnetic resonance imaging-determined
hippocampal volume in Alzheimer’s disease. Neuroscience 95: 721–725.
14. Gosche KM, Mortimer JA, Smith CD, Markesbery WR, Snowdon DA (2002)
Hippocampal volume as an index of Alzheimer neuropathology. Findings from
the Nun Study. Neurology 58: 1476–1482.
15. Huesgen CT, Burger PC, Crain BJ, Johnson GA (1993) In vitro MR microscopy
of the hippocampus in Alzheimer’s disease. Neurology 43: 145–152.
16. Barkhof F, Polvikoski TM, van Straaten ECW, Kalaria RN, Sulkava R, et al.
(2007) The significance of medial temporal lobe atrophy. A postmortem MRI
study in the very old. Neurology 69: 1521–1527.
17. Mortimer JA, Gosche KM, Riley KP, Markesbery WR, Snowdon DA (2004)
Delayed recall, hippocampal volume and Alzheimer neuropathology. Findings
from the Nun Study. Neurology 62: 428–432.
18. Dickson DW, Davies P, Bevona C, Van Hoeven KH, Factor SM, et al. (1994)
Hippocampal sclerosis: a common pathological feature of dementia in the very
old (.=80 years of age) humans. Acta Neuropathol 88: 212–221.
19. Zarow C, Sitzer TE, Chui HC (2008) Understanding hippocampal sclerosis in
the elderly: epidemiology, characterization, and diagnostic issues. Curr Neurol
Neurosci Rep 8: 363–370.
20. Ala TA, Beh GO, Frey WH (2000) Pure hippocampal sclerosis: A rare cause of
dementia mimicking Alzheimer’s disease. Neurology 54: 843–848.
21. Corey-Bloom J, Sabbagh MN, Bondi MW, Hansen L, Alford MF, et al. (1997)
Hippocampal sclerosis contributes to dementia in the elderly. Neurology 48:
154–160.
22. Colliot O, Che ´telat G, Chupin M, Desgranges B, Magnin B, et al. (2008)
Discrimination between Alzheimer Disease, Mild Cognitive Impairment, and
Normal Aging by using Automated Segmentation of the Hippocampus.
Radiology 248: 194–201.
23. Du AT, Schuff N, Amend D, Laakso MP, Hsu YY, et al. (2001) Magnetic
resonance imaging of the entorhinal cortex and hippocampus in mild cognitive
impairment and Alzheimer’s disease. J Neurol Neurosurg Psychiatry 71:
441–447.
24. Van Petten C (2004) Relationship between hippocampal volume and memory
ability in healthy individuals across the lifespan: Review and meta-analysis.
Neuropsychologia 42: 1394–1413.
25. Bennett DA, Schneider JA, Arvanitakis Z, Kelly JF, Aggarwal NT, et al. (2006)
Neuropathology of older persons without cognitive impairment from two
community-based studies. Neurology 66: 1837–1844.
26. Bennett DA, Schneider JA, Aggarwal NT, Arvanitakis Z, Shah R, et al. (2006)
Decision rules guiding the clinical diagnosis of Alzheimer’s disease in two
community-based cohort studies compared to standard practice in a clinic-based
cohort study. Neuroepidemiology 27: 169–176.
27. Bennett DA, Wilson RS, Schneider JA, Evans DA, Beckett LA, et al. (2002)
Natural history of mild cognitive impairment in older persons. Neurology 59:
198–205.
28. Boyle PA, Wilson RS, Aggarwal NT, Tang Y, Bennett DA (2006) Risk of
Alzheimer’s disease and rate of cognitive decline among persons with mild
cognitive impairment. Neurology 67: 441–445.
29. Schneider JA, Arvanitakis Z, Leurgans SE, Bennett DA (2009) Neuropathology
of probable AD and amnestic and non-amnestic MCI. Ann Neurol 66: 200–208.
30. Bennett DA, De Jager PL, Leurgans SE, Schneider JA (2009) Neuropathologic
intermediate phenotypes enhance association to Alzheimer susceptibility alleles.
Neurology 72: 1495–1503.
31. Wilson RS, Schneider JA, Boyle PA, Arnold SE, Tang Y, et al. (2007) Chronic
distress and incidence of mild cognitive impairment. Neurology 68: 2085–2092.
32. Dawe RJ, Bennett DA, Schneider JA, Vasireddi SK, Arfanakis K (2009)
Postmortem MRI of human brain hemispheres: T2 relaxation times during
formaldehyde fixation. Magn Reson Med 61: 810–818.
33. Pruessner JC, Li LM, Serles W, Pruessner M, Collins DL, et al. (2000)
Volumetry of Hippocampus and Amygdala with High-resolution MRI and
Three-dimensional Analysis Software: Minimizing the Discrepancies between
Laboratories. Cereb Cortex 10: 433–442.
34. Bennett DA, Schneider JA, Bienias JL, Evans DA, Wilson RS (2005) Mild
cognitive impairment is related to Alzheimer disease pathology and cerebral
infarctions. Neurology 64: 834–841.
35. Schneider JA, Wilson RS, Bienias JL, Evans DA, Bennett DA (2004) Cerebral
infarctions and the likelihood of dementia from Alzheimer disease pathology.
Neurology 62: 1148–1155.
36. National Institute on Aging, and Reagan Institute Working Group on Diagnostic
Criteria for the Neuropathological Assessment of Alzheimer’s Disease (1997)
Consensus recommendations for the postmortem diagnosis of Alzheimer’s
disease. Neurobiol Aging 18(S4): 1–2.
37. McKeith IG, Galasko D, Kosaka K, Perry EK, Dickson DW, et al. (1996)
Consensus guidelines for the clinical and pathologic diagnosis of dementia with
Lewy bodies (DLB): report of the consortium on DLB international workshop.
Neurology 47: 1113–1124.
38. Bennett DA, Schneider JA, Wilson RS, Bienia JL, Arnold SE (2004)
Neurofibrillary tangles mediate the association of amyloid load with clinical
Alzheimer’s disease and level of cognitive function. Arch Neurol 61: 378–384.
39. Arvanitakis Z, Leurgans SE, Wang Z, Wilson RS, Bennett DA, et al. (2011)
Cerebral Amyloid Angiopathy Pathology and Cognitive Domains in Older
Persons. Ann Neurol 69: 320–327.
40. Schneider JA, Boyle PA, Arvanitakis Z, Bienias JL, Bennett DA (2007)
Subcortical infarcts, Alzheimer’s disease pathology, and memory function in
older persons. Ann Neurol 62: 59–66.
41. Styner M, Oguz I, Xu S, Brechbu ¨hler C, Pantazis D, et al. (2006) Framework for
the statistical shape analysis of brain structures using SPHARM-PDM. Insight J,
Available: http://www.insight-journal.org/browse/publication/101 via the
Internet. Accessed 24 Jun 2011.
42. Paniagua B, Styner M, Macenko M, Pantazis D, Niethammer M (2009) Local
shape analysis using MANCOVA. Insight J, Available: http://www.insight-
journal.org/browse/publication/694 via the Internet. Accessed 24 Jun 2011.
43. Erten-Lyons D, Woltjer RL, Dodge H, Nixon R, Vorobik R, et al. (2009)
Factors associated with resistance to dementia despite high Alzheimer disease
pathology. Neurology 72: 354–360.
44. Dickerson BC, Goncharova I, Sullivan MP, Forchetti C, Wilson RS, et al. (2001)
MRI-derived entorhinal and hippocampal atrophy in incipient and very mild
Alzheimer’s disease. Neurobiol Aging 22: 747–754.
45. Killiany RJ, Hyman BT, Gomez-Isla T, Moss MB, Kikinis R, et al. (2002) MRI
measures of entorhinal cortex vs hippocampus in preclinical AD. Neurology 58:
1188–1196.
46. Vargha-Khadem F, Gadian DG, Watkins KE, Connelly A, Van Paesschen W,
et al. (1997) Differential Effects of Early Hippocampal Pathology on Episodic
and Semantic Memory. Science 277: 376–380.
47. Tulving E, Markowitsch HJ (1998) Episodic and declarative memory: Role of
the hippocampus. Hippocampus 8: 198–204.
48. Cohen JD, Perlstein WM, Braver TS, Nystrom LE, Noll DC, et al. (1997)
Temporal dynamics of brain activation during a working memory task. Nature
386: 604–608.
49. Postle BR, Stern CE, Rosen BR, Corkin S (2000) An fMRI Investigation of
Cortical Contributions to Spatial and Nonspatial Visual Working Memory.
Neuro Image 11: 409–423.
50. Bucur B, Madden DJ, Spaniol J, Provenzale JM, Cabeza R, et al. (2008) Age-
related slowing of memory retrieval: Contributions of perceptual speed and
cerebral white matter integrity. Neurobiol Aging 29: 1070–1079.
51. Hugdahl K, Thomsen T, Ersland L (2006) Sex differences in visuo-spatial
processing: An fMRI study of mental rotation. Neuropsychologia 44:
1575–1583.
52. Bobinski M, Wegiel J, Tarnawski M, Reisberg B, Mlodzik B, et al. (1995)
Atrophy of hippocampal formation subdivisions correlates with stage and
duration of Alzheimer disease. Dementia 6: 205–210.
53. Simic G, Kostovic I, Winblad B, Bogdanovic N (1997) Volume and Number of
Neurons of the Human Hippocampal Formation in Normal Aging and
Alzheimer’s Disease. J Comp Neurol 379: 482–494.
Correlates of Hippocampal Atrophy
PLoS ONE | www.plosone.org 12 October 2011 | Volume 6 | Issue 10 | e2628654. West MJ, Coleman PD, Flood DG, Troncoso JC (1994) Differences in the
pattern of hippocampal neuronal loss in normal ageing and Alzheimer’s disease.
Lancet 344: 769–772.
55. Behl C (2000) Apoptosis and Alzheimer’s disease. J Neural Transm 107:
1325–1344.
56. Smale G, Nichols NR, Brady DR, Finch CE, Horton WE, Jr. (1995) Evidence
for Apoptotic Cell Death in Alzheimer’s Disease. Exp Neurol 133: 225–230.
57. Loo DT, Copani A, Pike CJ, Whittemore ER, Walencewicz AJ, et al. (1993)
Apoptosis is induced by b-amyloid in cultured central nervous system neurons.
Proc Natl Acad Sci USA 90: 7951–7955.
58. Behl C, Davis JB, Klier FG, Schubert D (1994) Amyloid b peptide induces
necrosis rather than apoptosis. Brain Res 645: 253–264.
59. Barber R, McKeith IG, Ballard C, Gholkar A, O’Brien JT (2001) A Comparison
of Medial and Lateral Temporal Lobe Atrophy in Dementia with Lewy Bodies
and Alzheimer’s Disease: Magnetic Resonance Imaging Volumetric Study.
Dement Geriatr Cogn Disord 12: 198–205.
60. Apostolova LG, Morra JH, Green AE, Hwang KS, Avedissian C, et al. (2010)
Automated 3D mapping of baseline and 12-month associations between three
verbal memory measures and hippocampal atrophy in 490 ADNI subjects.
Neuro Image 51: 488–499.
61. Wang L, Swank JS, Glick IE, Gado MH, Miller MI, et al. (2003) Changes in
hippocampal volume and shape across time distinguish dementia of the
Alzheimer type from healthy aging. Neuro Image 20: 667–682.
62. Li S, Shi F, Pu F, Li X, Jiang T, et al. (2007) Hippocampal Shape Analysis of
Alzheimer Disease Based on Machine Learning Methods. Am J Neuroradiol 28:
1339–1345.
63. Scher AI, Xu Y, Korf ESC, White LR, Scheltens P (2007) Hippocampal shape
analysis in Alzheimer’s disease: A population-based study. Neuroimage 36: 8–18.
64. Csernansky JG, Wang L, Swank J, Miller JP, Gado M, et al. (2005) Preclinical
detection of Alzheimer’s disease: hippocampal shape and volume predict
dementia onset in the elderly. Neuro Image 25: 783–792.
65. Braak H, Braak E (1991) Neuropathological stageing of Alzheimer-related
changes. Acta Neuropathol 82: 239–259.
66. Arnold SE, Hyman BT, Flory J, Damasio AR, Van Hoesen GW (1991) The
Topographical and Neuroanatomical Distribution of Neurofibrillary Tangles
and Neuritic Plaques in the Cerebral Cortex of Patients with Alzheimer’s
Disease. Cereb Cortex 1: 103–116.
Correlates of Hippocampal Atrophy
PLoS ONE | www.plosone.org 13 October 2011 | Volume 6 | Issue 10 | e26286